X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

ABPI In UK Sees Possibility of Revenue Clawback Rate Rise

Content Team by Content Team
7th February 2023
in Drug Development, News

The Association of the British Pharmaceutical Industry (ABPI) has urged the government to take prompt action in response to the planned UK statutory revenue clawback rate increase for branded medications.

The Department of Health and Social Care (DHSC) is now conducting a significant consultation over proposals to increase from 24.4% to 27.5% of the statutory revenue clawback rate paid by businesses subject to the Statutory Scheme for branded medications. It’s approximately three times what companies may have predicted only a few years ago.

The Association of the British Pharmaceutical Industry (ABPI) cautioned that the anticipated rate hike could send the wrong signal to global investors and boardrooms at a time when the UK life sciences sector is already facing substantial problems.

The pharmaceutical sector prefers that the statutory scheme rate remain fixed. It will give the government and industry time to finalise critical discussions on the new voluntary scheme. The ABPI has requested that the current tariff be phased down at the end of 2023 to avoid further lowering prospective long-term life science investment in the UK. Once a new framework has been established, a fresh rate can be zeroed upon at the year’s end.

The hike is intended to imitate a similar record clawback rate increase from 15% to 26.5% announced last year under a comparable Voluntary Payment Assistance Scheme (VPAS). The agreement states that any medicine used by the NHS that exceeds a 2% nominal growth cap is completely subsidised by the industry. Before the pandemic, there had been an average clawback rate of 7%. Worldwide pharma R&D in the UK has decreased over the last 10 years dipping from 2012’s 4.9% to 3.2% in 2022.

Patient access to industry clinical trials has decreased by 44% vis-à-vis 2017/2018. While significant gains have been made as a result of restricted NHS England access accords, unjustified variation in the medicines supply across the UK persists. Two years after a drug’s introduction, the NHS in the UK is often behind other countries by 64% when it comes to using NICE-recommended medications.

Medicines spending will have fallen by 12% in real terms between 2019 and 2023. During this time, the government has increased funding to the NHS by 8%. The ABPI highlighted that the recent policy has resulted in disinvestment in medicines due to a decade-long growth cap.

In comparison to other main EU countries such as Italy, Spain, Germany, and France, the UK has had the greatest fall in its global proportion of new pharmaceutical launches between 2016 and 2021. The drop in pharmaceutical spending is affecting patient outcomes in the United Kingdom. Future negotiations between business and government will be cantered on developing a new, sustainable framework that supports the Life Sciences Vision’s ambitious goals, produces top-notch patient outcomes, ensures the financial viability of the NHS, and creates a sustainable sector that can continue to invest in tomorrow’s drugs and vaccines.

The government must take advantage of this chance to demonstrate that it comprehends the true issues affecting their industry and that it is prepared to collaborate with them to solve this system and let UK return to the path of innovation-led growth, said Richard Torbett, Chief Executive of the ABPI.

Previous Post

Pembrolizumab And Chemo-Boon To Endometrial Cancer Survival

Next Post

NICE Urged To Make The Kidney Cancer Treatment A Priority

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post

NICE Urged To Make The Kidney Cancer Treatment A Priority

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In